Sensus Healthcare, Inc - SRTS STOCK NEWS

Sensus Healthcare (Nasdaq: SRTS), based in Boca Raton, Fla., will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13 to 15, 2021. CEO Joe Sardano's presentation will be accessible via a webcast starting at 7:00 am (EST) on September 13. Sensus Healthcare specializes in non-invasive treatments for both oncological and non-oncological conditions, featuring technologies like the Sculptura™ and SRT-100™ systems, aimed at enhancing patient quality of life.

Sensus Healthcare (SRTS) reported Q2 2021 revenues of $5.4 million, a 358% increase year-over-year and 77% sequentially. The net loss narrowed to $(0.3) million or $(0.02) per share, improving from $(2.6) million or $(0.16) per share in Q2 2020. The company shipped 17 systems, enhancing its installed base to 515 systems. Cash stood at $15.2 million with no long-term debt. Management expressed optimism for continued growth, aided by new reimbursement schedules and an expanded international strategy, particularly in China and India.

Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on August 5, 2021, at 4:30 p.m. Eastern to discuss its Q2 2021 financial results and provide business updates. The call will be accessible via dial-in numbers and a live webcast. Sensus is focused on non-invasive medical treatments for various conditions, including its Sculptura™ and SRT systems for cancer treatment and skin conditions. This call aims to communicate recent achievements and future milestones.

Sensus Healthcare (Nasdaq: SRTS), a leader in non-invasive medical devices, announced management's participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021. The conference will facilitate one-on-one virtual meetings with investors. Sensus specializes in innovative treatments for oncological and non-oncological conditions, including the Sculptura™ system for radiation therapy and SRT-100™ for treating skin cancers. The company's focus is on enhancing patient quality of life through advanced technologies.

Sensus Healthcare reported an 83% revenue increase year-over-year, achieving $3.1 million in the first quarter of 2021 compared to $1.7 million in 2020. The company installed its 500th unit and narrowed its net loss to $1.1 million or $0.07 per share, down from $3.6 million or $0.22 per share last year. Gross profit rose to $1.6 million, with a gross margin of 51.6%. Cash and equivalents totaled $13.7 million as of March 31, 2021. Management anticipates continued revenue growth driven by higher reimbursement rates and expanding market acceptance.

Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a conference call on May 6, 2021, at 4:30 p.m. Eastern Time to discuss its Q1 2021 financial results and provide a business update. The call will be accessible via dial-in numbers (888-390-3967 for U.S. and Canada; 862-298-0702 for international) and a live webcast. Sensus Healthcare specializes in non-invasive medical devices for oncological and non-oncological conditions, including the Sculptura™ system and SRT-100™ technology for skin cancer treatments, emphasizing innovation in patient care.

Sensus Healthcare (Nasdaq: SRTS) announced a significant milestone as its SRT-100™ system successfully treated its first canine patient, Daisy, at Colorado State University's Flint Animal Cancer Center. Daisy had two mast cell tumors that were reduced after six treatments, avoiding surgery. This landmark event highlights Sensus's innovations in superficial radiation therapy (SRT), expanding the potential use of their technology in veterinary medicine. The partnership aims to develop treatment protocols and publish clinical data, promoting the commercial viability of SRT-100 in a new market.

Sensus Healthcare, Inc. (NASDAQ: SRTS), a leader in innovative medical devices, announced participation in three virtual investment conferences in March 2021. Key events include the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, the Roth Conference featuring a live panel on March 16, and the Maxim Group Emerging Growth Conference on March 17-18. These conferences offer opportunities for one-on-one meetings with institutional investors. Sensus specializes in non-invasive treatments for oncological and non-oncological conditions, enhancing patient care globally.

Sensus Healthcare (SRTS) reported a fourth-quarter net income of $1.0 million on revenues of $5.1 million, down from $8.5 million in Q4 2019. Despite shipping 18 systems, including sales in China, the revenue drop is attributed to COVID-19 impacts. The company achieved a 63.4% gross profit margin. Major highlights include increased Medicare reimbursement rates and promising clinical studies on superficial radiation therapy (SRT) for keloid treatment. The company's cash reserves stood at $14.9 million as of December 31, 2020, with a focus on recovery in the upcoming year.